Poor reporting of adverse effects in clinical trials: in urology too.
A study published in 2010 showed that a large proportion of published clinical trials in urological indications did not mention adverse effects (28%), including in the abstract (36%), the introduction (47%) and the discussion (34%). Only 14% of publications specified the types of adverse effects that were assessed. Severity was only reported in one-fifth of trials. Yet treatment choices must be based not only on the expected benefits but also on the potential harms.